Two pieces of news provide a flicker of hope amid the doom and gloom.
FDA approval would expand that practice and could make the highly expensive medicine more affordable and may lead many more insurance companies to pay for the drug.. ...
Insiders know more, are better prepared and generally more successful. Today's top advisors subscribe to our premium newsletter to ensure that they don't miss out the most important industry changes that are happening in real time. Starting at $8.95/Mo.